An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin; Fluorouracil
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jun 2018 Planned initiation date changed from 1 May 2018 to 30 Jun 2018.
- 04 Jun 2018 New trial record